Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Chiome Bioscience's Revenue for the
three
months ended in Dec. 2025 was 円223.5 Mil. Chiome Bioscience's average Accounts Receivable for the
three
months ended in Dec. 2025 was 円59.7 Mil.
Hence, Chiome Bioscience's Receivables Turnover for the
three
months ended in Dec. 2025 was 3.74.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Chiome Bioscience Receivables Turnover Related Terms
Chiome Bioscience Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Chiome Bioscience's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience (TSE:4583) has a Receivables Turnover of 3.74 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Chiome Bioscience and its competitors. According to the industry distribution chart, Chiome Bioscience ranks #211 out of 841 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Chiome Bioscience's Receivables Turnover too high?
Chiome Bioscience's current Receivables Turnover is 3.74. The Biotechnology industry median Receivables Turnover is 5.27. Chiome Bioscience's value of 3.74 is 29% below this industry median. Based on the distribution chart, Chiome Bioscience ranks #211 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chiome Bioscience has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #211 out of 841 companies for Receivables Turnover. This puts Chiome Bioscience in the upper half of its industry. The industry median Receivables Turnover is 5.27. Chiome Bioscience's value of 3.74 is 29% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chiome Bioscience's current Receivables Turnover of 3.74 is 29% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Chiome Bioscience and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current Receivables Turnover is 3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円105.87, compared to a current price of 円68.00 — trading 35.8% below its estimated fair value. The current Receivables Turnover is 3.74 and 29% below the Biotechnology industry median of 5.27. Chiome Bioscience's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Receivables Turnover is 3.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued.
The current stock price of 円68.00 is trading 35.8% below its estimated GF Value™ of 円105.87.
GuruFocus considers Chiome Bioscience to be Possible Value Trap.
Key valuation signals for TSE:4583:
Receivables Turnover: 3.74
GF Value™: 円105.87 vs. price of 円68.00 (35.8% below fair value)
Industry Position: 29% below the Biotechnology median (#211 of 841)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
39GF Score
Get the complete analysis for TSE:4583
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
